Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $96
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $86 to $96.
August 09, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Apellis Pharmaceuticals and raises the price target from $86 to $96.
The raised price target and maintained Outperform rating by a reputable analyst are positive signals for investors, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100